ArticleJournal of nanobiotechnology2026
A three-pronged strategy with minimalist nattokinase nanocomposite eye drops breaks the vicious cycle in ultraviolet-B-induced cataract.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCataract remains the most prevalent cause of visual impairment and irreversible blindness worldwide. It is characterized by lens opacification arising from crystallin denaturation, leading to variable degrees of vision loss and poor quality of life. Although crystallin denaturation is the primary pathological basis of cataract, oxidative stress and inflammation also play significant roles.
resultsIt was first confirmed that nattokinase (NK) could degrade cataractous tissue and alleviate the opacification using human cataract phacoemulsification fluid, thus supporting the in vivo anti-cataract efficacy of NK-based nanocomposites (NNs). Herein, we developed minimalist NNs as eye drops, through electrostatic self-assembly between NK and natural macromolecules. The NNs exert three-pronged therapeutic effects (antioxidant, anti-inflammatory, and anti-crystallin denaturation) that disrupt the pathological cycle in cataract. The in vitro cellular studies demonstrated that the NNs were internalized via receptor-mediated endocytosis and micropinocytosis, and efficiently achieved a synergistic scavenging effect of reactive oxygen species (ROS). In ultraviolet B (UVB)-induced cataract mice, the NNs successfully suppressed oxidative stress and inflammation, while protecting crystallins through enhanced intracorneal retention, ultimately ameliorating lens opacity index. Moreover, further analysis revealed that NNs effectively inhibited ROS accumulation by up to 15.78-fold, along with the ROS/NLRP3/pyroptosis axis and the denaturation of crystallins, thereby offering new insights into therapeutic regimens for cataract.
conclusionsConsequently, the NNs alleviated lens opacification by breaking the cataract vicious cycle through a three-pronged inhibition of oxidative stress, inflammation, and crystallin denaturation. Our findings pave the way for utilizing NNs as a novel strategy for reversing cataract, as well as associated ocular disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.